Bio-Path Holdings Presents at 2020 American Association for Cancer Research Annual Meeting
April 27 2020 - 9:00AM
Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company
leveraging its proprietary DNAbilize® antisense RNAi nanoparticle
technology to develop a portfolio of targeted nucleic acid cancer
drugs, today announces the presentation of a poster highlighting
the clinical trial design of its Phase 1 study of BP1002 at the
2020 American Association for Cancer Research (AACR) Annual Meeting
being held virtually from April 27-28, 2020.
The poster, titled, “A Phase I Clinical Trial to Study the
Safety, Pharmacokinetics, and Efficacy of BP1002 (L-Bcl-2)
Antisense Oligonucleotide in Patients with Advanced Lymphoid
Malignancies,” was presented virtually by Dr. Ana Tari Ashizawa,
Senior Vice President of Research, Development and Clinical Design
at Bio-Path Holdings.
"We are particularly pleased to have our Phase 1 clinical
development program for BP1002 as a potential therapy for lymphoma
and chronic lymphocytic leukemia patients highlighted in a poster
at this important scientific meeting," stated Peter Nielsen,
President and Chief Executive Officer of Bio-Path Holdings. "We
believe this poster will enhance visibility for our Bcl-2 program
among an audience of world-leading oncologists and cancer
researchers."
The Phase 1 clinical trial is expected to be conducted at
several leading cancer centers, including The University of Texas
MD Anderson Cancer Center, the Georgia Cancer Center and the Sarah
Canon Research Institute. Initially, a total of six evaluable
patients will be treated with BP1002 monotherapy in a standard 3+3
design, with a starting dose of 20 mg/m2. The approved treatment
cycle is two doses per week over four weeks, resulting in eight
doses administered over 28 days. The primary objective of the study
is to evaluate the safety and tolerability of escalating doses of
BP1002.
BP1002 targets the protein Bcl-2, which is responsible for
driving cell survival in up to 60% of all cancers. High expression
of Bcl-2 has been correlated with adverse prognosis for patients
diagnosed with relapsed, aggressive non-Hodgkin’s lymphoma.
Preclinical studies have shown BP1002 to be a potent inhibitor
against the Bcl-2 target, and Bio-Path believes that its benign
safety profile should enable BP1002 combination therapy with
approved agents.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a
novel technology that has yielded a pipeline of RNAi nanoparticle
drugs that can be administered with a simple intravenous
transfusion. Bio-Path’s lead product candidate, prexigebersen
(BP1001, targeting the Grb2 protein), is in a Phase 2 study for
blood cancers and is under consideration by the FDA to commence
Phase 1 studies in solid tumors. This is followed by BP1002,
targeting the Bcl-2 protein, where it will be evaluated in lymphoma
and solid tumors clinical studies.
For more information, please visit the Company's website at
http://www.biopathholdings.com.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws. These statements are based on management's current
expectations and accordingly are subject to uncertainty and changes
in circumstances. Any express or implied statements contained in
this press release that are not statements of historical fact may
be deemed to be forward-looking statements. Any statements that are
not historical facts contained in this release are forward-looking
statements that involve risks and uncertainties, including the
impact, risks and uncertainties related to COVID-19 and actions
taken by governmental authorities or others in connection
therewith, Bio-Path’s ability to raise needed additional capital on
a timely basis in order for it to continue its operations, have
success in the clinical development of its technologies, the timing
of enrollment and release of data in such clinical studies and the
accuracy of such data, limited patient populations of early stage
clinical studies and the possibility that results from later stage
clinical trials with much larger patient populations may not be
consistent with earlier stage clinical trials, and such other risks
which are identified in Bio-Path's most recent Annual Report on
Form 10- K, in any subsequent quarterly reports on Form 10-Q and in
other reports that Bio-Path files with the Securities and Exchange
Commission from time to time. These documents are available on
request from Bio-Path Holdings or at www.sec.gov. Bio-Path
disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contact
Information:Investors
Will O’ConnorStern Investor Relations
212-362-1200will@sternir.com
Doug Morris Investor Relations Bio-Path Holdings, Inc.
832-742-1369
Bio Path (NASDAQ:BPTH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bio Path (NASDAQ:BPTH)
Historical Stock Chart
From Sep 2023 to Sep 2024